Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study

Improved therapeutic options are needed for patients with treatment-refractory nontuberculous mycobacterial lung disease caused by complex (MAC). To evaluate the efficacy and safety of daily amikacin liposome inhalation suspension (ALIS) added to standard guideline-based therapy (GBT) in patients wi...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:American journal of respiratory and critical care medicine Ročník 198; číslo 12; s. 1559 - 1569
Hlavní autori: Griffith, David E., Eagle, Gina, Thomson, Rachel, Aksamit, Timothy R., Hasegawa, Naoki, Morimoto, Kozo, Addrizzo-Harris, Doreen J., O’Donnell, Anne E., Marras, Theodore K., Flume, Patrick A., Loebinger, Michael R., Morgan, Lucy, Codecasa, Luigi R., Hill, Adam T., Ruoss, Stephen J., Yim, Jae-Joon, Ringshausen, Felix C., Field, Stephen K., Philley, Julie V., Wallace, Richard J., van Ingen, Jakko, Coulter, Chris, Nezamis, James, Winthrop, Kevin L.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States American Thoracic Society 15.12.2018
Predmet:
ISSN:1073-449X, 1535-4970, 1535-4970
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Buďte prvý, kto okomentuje tento záznam!
Najprv sa musíte prihlásiť.